RNActive cancer immunotherapy / CureVac - LARVOL DELTA

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update (ACCESSWIRE) - "CureVac continues to develop the next generation of targeted mRNA-based cancer vaccines by combining cutting-edge technologies for antigen discovery with its second-generation mRNA backbone. The initial focus is on the development of off-the-shelf cancer vaccines targeting tumor antigens shared across different patient populations and/or tumor types....For the first, off-the-shelf approach, CureVac expects to select two clinical candidates for shared-antigen cancer vaccines in solid tumor and hematological cancers, including one in collaboration with researchers at the University of Texas M.D. Anderson Cancer Center, by the end of 2025, with plans to initiate two additional Phase 1 studies by the end of 2026."

New P1 trial • Pipeline update • Hematological Malignancies • Solid Tumor

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update (Issuer Direct) - "CureVac recently presented preclinical studies supporting the potency of a multiepitope mRNA cancer vaccine construct targeting tumors in a murine melanoma model....A multiepitope mRNA construct encoding ten epitopes derived from the murine B.16.F10 melanoma cell line was tested in mice....Data obtained on day 21 confirmed prominent induction of CD8+ and CD4+ T cell responses recognizing epitopes across the full multiepitope construct. Median survival of the animals increased to 30.9 days for treated mice compared to 23.2 days for a group vaccinated with formulated control mRNA."

Preclinical • Melanoma